Kotanko P, Margreiter R, Pfaller W
Department of Internal Medicine, Krankenhaus Barmherzige Brüder (Marschallgasse), Graz, Austria.
Transplantation. 1996 Feb 15;61(3):388-92. doi: 10.1097/00007890-199602150-00011.
The excretion of urinary N-acetyl-beta-D-glucosaminidase (NAG) was measured daily between day 7 and day 28 in 33 renal allograft recipients enjoying an entirely uncomplicated first postoperative month. Graft status was evaluated after 4 and 6 years and related to NAG excretion. After 4 years, 6 patients had experienced graft loss due to chronic rejection. Posttransplant urinary NAG excretion in the group of patients with failing grafts was significantly lower (9.4 +/- 6.3 vs. 17.2 +/- 8.5 U/g urinary creatinine, P = 0.036). Univariant analysis of recipient and donor characteristics revealed urinary NAG excretion to be the only parameter significantly differing between the groups. After 6 years, a total of 8 patients had lost their grafts. The posttransplant urinary NAG excretion in this group was 10.8 +/- 6.2 U/g; in the 25 patients with functioning grafts NAG excretion was 17.4 +/- 8.8 U/g (P = 0.064). A very low urinary NAG excretion ( < 7 U/g) was seen in 5 patients and associated with poor graft survival after 4 and 6 years (odds ratios 12.5 (1.9-82.1) and 6.9 (1.1-44.8), respectively. Kaplan-Meier analysis showed a reduced graft survival in this subgroup (P = 0.031). Receiver operating characteristics (ROC) analysis demonstrated an association between low NAG excretion and graft survival rates both at 4 and 6 years (area under the ROC curve 0.799 +/- 0.115, P, 0.05, and 0.747 +/- 0.104, P < 0.05, respectively). Cox proportional hazards analysis identified a low urinary NAG excretion as an independent prognostic risk factor. Urinary NAG excretion was expressed as unit per gram of urinary creatinine; as the amount of NAG excreted depends on the graft mass, and the amount of urinary creatinine depends on the recipient body mass, a low NAG excretion (in terms of U/g urinary creatinine) could be a surrogate marker of an unfavorable low graft to body weight ratio, which, in turn, might be associated with a reduced graft survival.
在33例术后第一个月完全无并发症的肾移植受者中,于第7天至第28天每天测量尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)的排泄量。在4年和6年后评估移植肾状态,并将其与NAG排泄量相关联。4年后,6例患者因慢性排斥反应导致移植肾失功。移植肾失功组患者移植后尿NAG排泄量显著降低(9.4±6.3 vs. 17.2±8.5 U/g尿肌酐,P = 0.036)。对受者和供者特征进行单变量分析显示,尿NAG排泄量是两组间唯一有显著差异的参数。6年后,共有8例患者移植肾失功。该组移植后尿NAG排泄量为10.8±6.2 U/g;在25例移植肾功能良好的患者中,NAG排泄量为17.4±8.8 U/g(P = 0.064)。5例患者尿NAG排泄量极低(<7 U/g),且与4年和6年后移植肾存活率低相关(优势比分别为12.5(1.9 - 82.1)和6.9(1.1 - 44.8))。Kaplan - Meier分析显示该亚组移植肾存活率降低(P = 0.031)。受试者工作特征(ROC)分析表明,低NAG排泄量与4年和6年时的移植肾存活率均相关(ROC曲线下面积分别为0.799±0.115,P < 0.05,以及0.747±0.104,P < 0.05)。Cox比例风险分析确定低尿NAG排泄量是一个独立的预后危险因素。尿NAG排泄量以每克尿肌酐的单位数表示;由于排泄的NAG量取决于移植肾质量,而尿肌酐量取决于受者体重,低NAG排泄量(以U/g尿肌酐计)可能是移植肾与体重比不利降低的替代标志物,这反过来可能与移植肾存活率降低相关。